跳至主要内容
临床试验/CTRI/2023/06/054242
CTRI/2023/06/054242已完成Unknown

A study to evaluate the Safety and efficacy of the TonEQ for Spot Reduction, Even Skin Tone and Skin Health improvement in healthy subjects. - NI

Transformative Learning Solutions Pvt Ltd0 个研究点目标入组 75 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Female adult subjects in general good health as determined from a re-cent medical history, general physical examination, dermatological as-sessment.
  • 2.Subjects in the age group of 40-60 years (both ages inclusive).
  • Subject with Fitzpatrick skin types III to V
  • 3.Each subject should have hyperpigmentary regions (may or at least one spot of 3mm size)
  • 4. Subject free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face.
  • 5.Subject who agrees not to use any other product/treatment/home remedy/ except the provided products on their face during the study period other than the test product.
  • 6.Subjects who agree not to carry out bleaching or any other procedures in-cluding facial etc. on face during the study period.
  • 7.Subjects who agree not to expose to excessive sun light. (Sun exposure not more than half an hour daily and during that time use of umbrella to cover face).
  • 8.Subjects willing to give a voluntary written informed consent, photog-raphy release and agree to come for regular follow-up.
  • 9.Subjects willing to abide by and comply with the study protocol.

排除标准

  • 1. Subject with any other signs of significant local irritation or skin disease.
  • 2.Subject currently taking any medication, which the Investigator believes may influence the interpretation of the data.
  • 3.Subject having clinically significant systemic or cutaneous disease, chronic illness or had major surgery in the last year.
  • 4.Subjects who do not agree to remove all jewelry on/around face (e.g., necklace, earrings, if possible, nose ring), during Digital imaging.
  • 5.Subjects having hair style which covers almost the entire forehead
  • 6.Subjects undergoing any treatment of any skin condition on their face/forearm.
  • Subjects not willing to discontinue other topical facial products.
  • 7.Subject allergic or sensitive to bar cleansing products, cosmetics, creams/lotions, artificial jewellery or anything else.
  • 8.Pregnant women (as confirmed by UPT) and lactating women
  • 9.Subjects on any medical treatment either systemic/topical in the past 1 month or currently taking medication including food supplements.

研究者

发起方
Transformative Learning Solutions Pvt Ltd

相似试验

进行中(未招募)
1 期
A Study to Evaluate the Safety and efficacy of the Antibody APX005M in Adult Patients with Metastatic Melanoma Who have not Received Prior Immunotherapynresectable or metastatic melanomaMedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864
EUCTR2018-003864-30-ESApexigen, Inc.36
进行中(未招募)
1 期
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864
EUCTR2018-003866-14-ESApexigen, Inc.174
进行中(未招募)
1 期
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864
EUCTR2018-003866-14-FRApexigen, Inc.174
进行中(未招募)
不适用
A study to determine the safety and efficacy of a terbinafine topical formulation system in subjects with onychomycosis in laser treated toenails versus ciclopirox lacquer in intact toenailsDistal/lateral Subungual onychomycosis (DSO) caused by dermatophytesMedDRA version: 8.1Level: LLTClassification code 10030338Term: Onychomycosis
EUCTR2006-005895-42-ISTLT Medical Ltd.235
已完成
不适用
Safety and effectiveness of TOPS™ SystemSingle Level Lumbar Spine Stenosis (with up to a grade 1 spondylolisthesis)Surgery
ISRCTN47205504Premia Spine Ltd (Israel)10